LLY — Eli Lilly and Company

Summary of Eli Lilly Q1 2026 Earnings Call

1. Key Financial Results and Metrics

• Revenue Growth: Q1 2026 revenue increased by 56% year-over-year, reaching approximately $20 billion, driven by strong performances from key products.
• Key Product Performance: Major products, including Mounjaro and Semaglutide, contributed over $7 billion in growth. Immunology, oncology, and neuroscience segments collectively grew by 160%.
• Gross Margin: Gross margin was 82.6%, a slight decrease of 1 percentage point from Q1 2025, primarily due to lower prices.
• Operating Expenses: Marketing, selling, and administrative expenses rose by 19%, while R&D expenses increased by 28% due to ongoing investments in the pipeline.
• Earnings Per Share: Non-GAAP EPS was $8.55, significantly up from $3.34 in Q1 2025, despite acquisition-related R&D charges.

2. Strategic Updates and Business Highlights

• Product Launch: Foundayo, an oral GLP-1 therapy for weight management, received FDA approval and is positioned as a scalable solution for obesity, with ongoing regulatory reviews in over 40 countries.
• Pipeline Advancements: Positive Phase III data were reported for several products, including retatrutide and ixekizumab, with multiple new Phase III programs initiated.
• Acquisitions: Lilly announced acquisitions of several companies, including Orna Therapeutics and Ajax Therapeutics, to enhance its pipeline and capabilities.
• Access Initiatives: The Lilly Employer Connect program was launched to improve access to obesity medications for employees, and the Medicare GLP-1 bridge program was extended, enhancing access for seniors.

3. Forward Guidance and Outlook

• Revenue Guidance: Full-year revenue is now expected to be between $82 billion and $85 billion, an increase of $2 billion at both ends of the range, reflecting strong performance from Mounjaro and Semaglutide.
• Earnings Guidance: Non-GAAP EPS guidance was raised to a range of $35.50 to $37.00.
• Market Dynamics: Despite price declines expected to be a headwind in the low to mid-teens, the company anticipates continued strong growth driven by volume.

4. Bad News, Challenges, or Points of Concern

• Pricing Pressure: U.S. prices declined by 7%, with an expected overall price headwind impacting margins, particularly in the obesity medication market.
• Market Competition: The entry of generic semaglutide in certain markets could pose competitive challenges, although initial data suggests it may stimulate overall market growth.
• Regulatory and Access Risks: While the Medicare GLP-1 bridge program is a positive development, the long-term sustainability of access and reimbursement remains uncertain.

5. Notable Q&A Insights

• Pricing and Volume Dynamics: CEO Dave Ricks emphasized that the obesity market behaves differently from traditional pharmaceuticals, with volume growth often outpacing price reductions.
• International Launch Insights: The international launch of Mounjaro has exceeded expectations, with strong market share gains, particularly in countries like Brazil and China.
• Employer Connect Program: The Employer Connect initiative aims to improve employer buy-in for obesity medications, with gradual impacts expected as data on effectiveness and cost savings are published.
• Foundayo Launch Confidence: Early metrics for Foundayo's launch are positive, with a focus on building prescriber familiarity and consumer awareness before a full-scale marketing push.

Overall, Eli Lilly's Q1 2026 results reflect robust growth and strategic advancements, particularly in the obesity treatment space, while navigating challenges related to pricing pressures and competition.